STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKTX
  4. [Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

Akari CEO Shows Confidence: Increases Stake with $7,000+ Stock Purchase

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Insider Trading Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has increased his position through two separate purchases of American Depositary Shares (ADS):

  • June 23, 2025: Acquired 943 ADS at $1.15 per share
  • June 24, 2025: Acquired 5,203 ADS at weighted average price of $1.16

Following these transactions, Gaslightwala now directly owns 277,574 ADS. Each ADS represents 2,000 ordinary shares with $0.0001 par value. The insider's accumulation of shares at these price levels may signal management's confidence in the company's prospects. The Form 4 was filed within the required reporting timeframe and executed by Torsten Hombeck as Attorney-in-Fact.

Positive

  • CEO Abizer Gaslightwala demonstrated confidence through open market purchases of 6,146 ADSs worth approximately $7,100 over two days at $1.15-$1.16 per share

Negative

  • None.
Insider Gaslightwala Abizer
Role President & CEO
Bought 6,146 shs ($7K)
Type Security Shares Price Value
Purchase American Depositary Shares representing Ordinary Shares 5,203 $1.16 $6K
Purchase American Depositary Shares representing Ordinary Shares 943 $1.15 $1K
Holdings After Transaction: American Depositary Shares representing Ordinary Shares — 277,574 shares (Direct)
Footnotes (1)
  1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many AKTX shares did CEO Abizer Gaslightwala purchase in June 2025?
CEO Abizer Gaslightwala purchased a total of 6,146 American Depositary Shares (ADS) over two days: 943 shares at $1.15 per share on June 23, 2025, and 5,203 shares at an average price of $1.16 on June 24, 2025.

What is AKTX CEO's total share ownership after the June 2025 purchases?
Following the reported transactions, CEO Abizer Gaslightwala directly owns 277,574 American Depositary Shares of Akari Therapeutics (AKTX). Each ADS represents 2,000 Ordinary Shares of the company.

What was the purchase price range for AKTX shares in the CEO's June 24, 2025 transaction?
On June 24, 2025, the CEO purchased shares at prices ranging from $1.15 to $1.16 per share, with a weighted average price of $1.16. The exact number of shares purchased at each price point within this range was not disclosed in the filing.

What positions does Abizer Gaslightwala hold at AKTX according to the Form 4?
According to the Form 4 filing, Abizer Gaslightwala serves as both a Director and President & CEO of Akari Therapeutics Plc (AKTX).
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gaslightwala Abizer
(Last) (First) (Middle)
C/O AKARI THERAPEUTICS PLC
22 BOSTON WHARF ROAD FL 7
(Street)
BOSTON MA 02210
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares representing Ordinary Shares(1) 06/23/2025 P 943 A $1.15 272,371 D
American Depositary Shares representing Ordinary Shares(1) 06/24/2025 P 5,203 A $1.16(2) 277,574 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.
/s/ Torsten Hombeck, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR